Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

New Data from SANBS Reinforces 5 Years of Success Preventing HIV and Hepatitis Transmission from Donated Blood


News provided by

South African National Blood Service

25 Jul, 2011, 07:00 GMT

Share this article

Share toX

Share this article

Share toX

JOHANNESBURG, July 25, 2011 /PRNewswire/ --

Since 2005, SANBS Has Eliminated Thousands of Transfusion-Transmittable Infections from the Blood Supply

The South African National Blood Service (SANBS) presented new data which demonstrated that its use of Novartis nucleic acid testing (NAT) products to screen donated blood for HIV and Hepatitis has resulted in a significant increase in the safety of the South African blood supply.  The data underscores SANBS' recent celebration of five years of successful effort to prevent the spread of HIV and Hepatitis from transfusion of infected blood.

In addition to reinforcing a remarkable public health story, the data provides further evidence that nucleic acid testing of each unit of blood individually (called individual donor testing, or ID-NAT) - rather than in pools of multiple donors - is the most sensitive method available for detecting HIV type 1 (the virus type responsible for 99.6% of all HIV infections), Hepatitis C virus, and Hepatitis B virus (HBV) in donated blood.

"Prior to NAT testing, transmission of HIV and Hepatitis infections from donated blood were not uncommon in South Africa," said Mr. Ravi Reddy, chief operations officer at SANBS.  "Since we started performing ID-NAT, we have virtually eliminated the risk, with no reports of HIV-1 infections from transfused blood or blood products. This represents a significant increase in patient safety in South Africa, and I hope this serves as a model for other countries."

Since 2005, SANBS has screened 3.8 million blood donations for HIV-1 RNA, HCV RNA, and HBV DNA using the Novartis Diagnostics Procleix Ultrio assay on the Procleix Tigris NAT blood screening platform. Because NAT provides highly sensitive detection of the genetic material of the virus itself (RNA and DNA), it can detect active infections that traditional serology testing can miss, shortening the time between infection and when detection of that infection is possible and also enabling detection of very low-level chronic infections. The full integration and automation of all steps of the NAT process, which are possible only with the Procleix TIGRIS system, enables efficient workflow for the laboratories performing the testing of large numbers of specimens daily. SANBS also conducts serology testing, which detects evidence of the body's immune response to infection (anti-HIV, anti-HCV, and HBsAg), on all samples.  

The SANBS results showed that the Novartis Diagnostics Procleix Ultrio assay identified 6,487 HIV-1-positive units of donated blood, 96 of which were not detected by serology and HIV p24 antigen testing alone.(1) In addition, there were 3,007 Hepatitis B-positive units of which 346 were not detected with serology testing alone, and 250 Hepatitis C-positive units of which 5 were not detected with serology testing alone. These units of infected blood would have tested negative and been made available for transfusion to patients if not removed from the blood supply following NAT testing.

According to UN AIDS, in 2007 there were 5.3 million HIV-infected people in South Africa, representing an overall national HIV prevalence rate of 11 percent.  This creates a greater risk of HIV-infected blood entering the blood supply, with some estimates showing that in South Africa there are as many as one HIV-1 infected unit of donated blood per 600 blood donations.

"As in any country, not all of those infected with HIV or Hepatitis are aware of their infection or of the dangers of having HIV and hepatitis enter the blood supply. This makes it essential that our blood screening programs employ a testing method that will help us deliver the safest possible blood," said Mr. Reddy. "The data shows that NAT in IDT has achieved that result in South Africa."

Notes to Editors

About HIV

The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the human immune system, destroying or impairing their function. The most common type of HIV is known as HIV-1, which is easily transmitted.

HIV-1 has caused the majority of AIDS cases(2) and represents 99.6% of all HIV infections.(3, 4)  In addition, according to The World Health Organization (WHO), 5-10% of all HIV infections worldwide have been acquired through transfusions of infected blood and blood products.(5)

An estimated 5.6 million people were living with HIV and AIDS in South Africa in 2009, more than in any other country.(6) It is believed that in 2009, an estimated 310,000 South Africans died of AIDS.(6) Prevalence is 17.8 percent among those aged 15-49, with some age groups being particularly affected.(6) Almost one-in-three women aged 25-29, and over a quarter of men aged 30-34, are living with HIV.(7)

About Hepatitis C Virus (HCV)

HCV infection is a viral disease that leads to inflammation of the liver and may cause lifelong infection, cirrhosis (scarring) of the liver, and liver cancer.(8, 9) An estimated 170 million people worldwide (3 percent) are chronically infected with HCV.(9) An estimated 3 to 4 million people are newly infected each year.(9) Most people who have been recently infected with HCV do not have symptoms, and in many cases, there may be no symptoms of the disease until cirrhosis has developed.(8)  The prevalence of HCV infection in South Africa is not known but has been estimated to be between 0.1 (2) and 1.7 %.(10)  HCV infection is more serious in persons with HIV, and leads to liver damage more quickly.(11)  Coinfection with HCV may also affect the treatment of HIV infection.(11)

About Hepatitis B Virus (HBV)

HBV infection is a major cause of acute and chronic liver disease. About one-third of the world's population has been infected with HBV.(12) Most of the serious consequences occur among people who develop chronic hepatitis B infection. About a million people with chronic hepatitis B die each year from cirrhosis and hepatocellular carcinoma.(12) HBV is second only to tobacco as the leading cause of cancer in humans.(12) It is estimated that over 50% of South Africans have been infected by the virus and at least 3 million people are chronic hepatitis B carriers.(12)

About SANBS

SANBS is a non-profit organisation, which provides a vein to vein blood transfusion service in 8 of the 9 provinces in SA. SANBS collects 780,000 units of blood annually (100% voluntary), and has two testing centres  (Johannesburg and Durban), seven blood processing centres, and 79 blood banks serving over 1,000 hospitals and clinics. SANBS is accredited with the South African National Accreditation System (SANAS).

References

1. Vermeulen, M., Reddy, R., Sensitivity of NAT Options: The SANBS Experience, South African National Blood Service (SANBS). (2011, June). Symposium conducted at the International Society of Blood Transfusion (ISBT) Congress, Lisbon, Portugal.

2. World Health Organization - About HIV page  http://www.who.int/hiv/abouthiv/en/

3. Kandathil AJ et al. 2005. Molecular epidemiology of HIV. Indian J Med Res. 121:333-344.

4. Buonaguro L et al. 2007. Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenic and Therapeutic Implications. J. Virol. 81(19):10209-10219.

5. World Health Organization http://www.searo.who.int/en/Section980/Section1162/Section1167/Section1171_4810.htm

6. UNAIDS (2010) 'UNAIDS report on the global AIDS epidemic'

7. Human Sciences Research Council (2009), 'South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2008: A Turning Tide Among Teenagers?'

8. PubMed Health http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001329/

9. World Health Organization - Hepatitis C page http://www.who.int/csr/disease/hepatitis/Hepc.pdf

10. WHO Weekly Epidemiologic Record. 1999;74:412-28

11. Centers for Disease Control and Prevention (CDC) http://www.cdc.gov/hiv/resources/factsheets/coinfection.htm

12. South African Vaccine and Immunisation Centre http://www.savic.ac.za/disease.php?sub3=88

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.